IPC Main Group
A61K 40/00 Cellular immunotherapy
Introduced: January 2025
Classification Context
- Section:
- HUMAN NECESSITIES
- Class:
- MEDICAL OR VETERINARY SCIENCE; HYGIENE
- Subclass:
- PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
Filing statistics
IPC A61K 40/00 belongs to the parent subclass A61K, which recorded 1,792,627 patent applications worldwide between 2013 and 2023. Annual filings declined from 147,606 in 2013 to 132,650 in 2023 (-10%), peaking at 177,518 applications in 2016. The most active applicants in class A61 are PHILIPS ELECTRONICS (18,523 applications), NOVARTIS (14,253 applications) and COVIDIEN (13,953 applications).
Source: EPO PATSTAT, worldwide filings
Additional Content
Medicinal preparations containing antigens or antibodies
5 direct subcodes
Child Classifications
Navigate with arrow keys, Enter to open
- A61K 40/1 characterised by the cell type used
- A61K 40/2 characterised by the effect or the function of the cells
- A61K 40/3 characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K 40/4 characterised by antigens that are targeted or presented by cells of the immune system
- A61K 40/5 characterised by the use of allogeneic cells
Top Applicants
Top 10 applicants by patent filingsfor class A61, 2013–2023, worldwide · Source: EPO PATSTAT
- PHILIPS ELECTRONICS NL 18,523
- NOVARTIS CH 14,253
- COVIDIEN US 13,953
- ROCHE CH 12,005
- CHINESE ACADEMY OF SCIENCES 11,955
- UNIVERSITY OF CALIFORNIA US 11,692
- HARVARD UNIVERSITY US 11,596
- L'OREAL FR 11,593
- P&G (PROCTER & GAMBLE COMPANY) US 11,297
- OLYMPUS CORPORATION JP 9,594